Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Hims & Hers Health Inc (NYSE:HIMS) is one of the best stocks on the New York Stock Exchange (NYSE), up 21.3% at $56.22 at last glance, earlier hitting a fresh record high of $56.71, after the ...